Table 3.

Univariate and multivariate Cox regression analysis of five-gene signature and clinicopathological characteristics with overall survival in the training and another two external validation datasets.

Variable	Training (TCGA) cohort					GSE21501 cohort					GSE79668 cohort
	N	Univariate		Multivariate		N	Univariate		Multivariate		N	Univariate		Multivariate
		P	HR (95% CI)	P	HR (95% CI)		P	HR (95% CI)	P	HR (95% CI)		P	HR (95% CI)	P	HR (95% CI)
AJCC stage
I-IIA vs. IIB-IV	48/125	0.012	1.93 (1.15-3.24)	0.68	1.37 (0.30-6.27)	26/71	0.044	1.83 (1.0-3.29)	0.059	1.83 (0.97-3.42)	13/38	0.25	1.52 (0.74-3.1)	0.98	0.97 (0.11-8.86)
T stage
T1/T2 vs. T3/T4	31/144	0.03	2.02 (1.07-3.81)	0.87	1.06 (0.51-2.23)	18/80	0.85	0.94 (0.51-1.74)	0.24	0.68 (0.36-1.30)	15/36	0.05	1.97 (0.97-3.98)	0.36	1.48 (0.63-3.49)
N stage
N0 vs. N+	50/118	0.003	2.16 (1.28-3.65)	0.58	1.48 (0.36-6.00)	28/73	0.035	1.83 (1.04-3.22)	0.087	1.74 (0.92-3.28)	14/37	0.29	1.44 (0.72-2.87)	0.96	0.97 (0.12-7.69)
Grade
G1/G2 vs. G3/G4	125/50	0.05	1.54 (0.99-2.37)	0.53	1.17 (0.72-1.89)
Gender
Female vs. male	80/97	0.31	1.24 (0.82-1.86)	0.51	0.86 (0.55-1.35)						19/32	0.501	1.24 (0.66-2.30)	0.87	1.05 (0.55-2.01)
Age (years)
>60 vs. ≤60	58/119	0.12	1.42 (0.90-2.24)	0.13	1.49 (0.89-2.51)						18/33	0.35	1.34 (0.72-2.49)	0.61	1.19 (0.61-2.31)
Signature
High vs. low risk	67/110	<0.0001	2.46 (1.62-3.73)	0.002	2.05 (1.29-3.24)	27/75	<0.001	2.61 (1.47-4.62)	0.005	2.31 (1.28-4.18)	38/13	0.0009	4.44 (1.83-10.73)	0.0044	3.84 (1.52-72)